Page last updated: 2024-10-16

adenine and Chronic Illness

adenine has been researched along with Chronic Illness in 52 studies

Research Excerpts

ExcerptRelevanceReference
"The frequency of homozygocity for the rare allele of the beta-fibrinogen gene (H2H2) was 13% for the periodontitis patients and 3% for the control group (P = 0."7.72Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis. ( De Nardin, E; Genco, RJ; Sahingur, SE; Sharma, A, 2003)
"Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment."7.72Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004)
"We recently identified a single R117H mutation in the cationic trypsinogen gene in several kindreds with an inherited form of acute and chronic pancreatitis (HP1), providing strong evidence that trypsin plays a central role in premature zymogen activation and pancreatitis."7.69Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. ( Aston, CE; Ehrlich, GD; Furey, W; Gabbaizedeh, D; Gates, LK; Gorry, MC; Preston, RA; Ulrich, C; Whitcomb, DC; Zhang, Y, 1997)
" Folic acid-induced acute kidney injury increased calvaria FGF23 mRNA and serum FGF23 and parathyroid hormone (PTH) levels at 6 h."3.83The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia. ( Durlacher, K; Hassan, A; Levi, R; Naveh-Many, T; Silver, J, 2016)
"The adenine-treated animals exhibited marked azotemia, impaired urinary concentrating capacity, intense tubular and glomerular damage, interstitial inflammation and fibrosis."3.79Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. ( Aminzadeh, MA; Nicholas, SB; Norris, KC; Vaziri, ND, 2013)
"After adenine dosing, significant hyperphosphatemia, hypocalcemia and secondary hyperparathyroidism (2HPT) were observed during the experimental period of 15 weeks."3.75Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels. ( Fujimori, A; Fukushima, S; Itoh, H; Mizukami, K; Nara, H; Okada, M; Sanagi, M; Takakura, K; Terai, K, 2009)
"The frequency of homozygocity for the rare allele of the beta-fibrinogen gene (H2H2) was 13% for the periodontitis patients and 3% for the control group (P = 0."3.72Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis. ( De Nardin, E; Genco, RJ; Sahingur, SE; Sharma, A, 2003)
"Resistant hepatitis B virus (HBV) strains develop in 30% of liver transplant recipients treated with lamivudine within 2 years from the time of transplantation."3.72Tenofovir therapy for lamivudine resistance following liver transplantation. ( Duncan, R; Lau, DT; Madariaga, JR; Montalbano, M; Muslu, H; Neff, GW; Nery, C; Nery, J; O'Brien, CB; Ruiz, P; Safdar, K; Schiff, ER; Shire, NJ; Tzakis, AG, 2004)
"Three HIV-infected patients with chronic hepatitis B (genotype A) were switched to adefovir therapy after unsuccessful lamivudine treatment."3.72Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment. ( Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L, 2004)
"We recently identified a single R117H mutation in the cationic trypsinogen gene in several kindreds with an inherited form of acute and chronic pancreatitis (HP1), providing strong evidence that trypsin plays a central role in premature zymogen activation and pancreatitis."3.69Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. ( Aston, CE; Ehrlich, GD; Furey, W; Gabbaizedeh, D; Gates, LK; Gorry, MC; Preston, RA; Ulrich, C; Whitcomb, DC; Zhang, Y, 1997)
"Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the advent of effective inhibitors of B-cell receptor signaling such as ibrutinib - a first-in-class inhibitor of BTK."2.94ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. ( Brown, JR; Cohen, A; Eichhorst, BF; Hilger, J; Hillmen, P; Huang, J; Lamanna, N; O'Brien, SM; Qiu, L; Salmi, T; Tam, CS; Wu, K, 2020)
"Acute renal failure is common in HIV-infected patients and is associated with acute infection and medication-related nephrotoxicity."2.44HIV-1 infection and the kidney: an evolving challenge in HIV medicine. ( de Silva, TI; Dockrell, DH; Griffin, MD; Post, FA, 2007)
"Moreover, treatment of bronchiolitis obliterans syndrome demonstrates heterogeneity in applied therapeutic options and sequence because of a lack of controlled data and different conclusions from already existing evidence."1.51Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. ( Ayuk, F; Ditschkowski, M; Gerbitz, A; Greinix, H; Halter, J; Hilgendorf, I; Holler, E; Jedlickova, Z; Klein, S; Kobbe, G; Lawitschka, A; Middeke, JM; Schäfer-Eckart, K; Stadler, M; Stelljes, M; Wagner-Drouet, E; Winkler, J; Wolff, D; Zeiser, R, 2019)
"Adenine-fed rats exhibited renal failure, ectopic calcification and altered serum parameters, including elevated levels of serum Pi, Cr, PTH and BUN."1.36Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications. ( Ikeda, R; Imai, Y; Maruyama, W; Mizoguchi, K, 2010)
"Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA."1.36The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors. ( Antonioli, L; Awwad, O; Blandizzi, C; Colucci, R; Da Settimo, F; Duranti, E; Fornai, M; Ghisu, N; La Motta, C; Natale, G; Tuccori, M; Virdis, A, 2010)
"Secondary hyperparathyroidism is characterized by increased parathyroid hormone (PTH) mRNA stability that leads to increased PTH mRNA and serum PTH levels."1.35Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD. ( Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J, 2009)
"Severe forms of periodontitis are suggested to have a genetic basis."1.32Association of the -1087 IL 10 gene polymorphism with severe chronic periodontitis in Swedish Caucasians. ( Berglundh, T; Donati, M; Hahn-Zoric, M; Hanson, LA; Padyukov, L, 2003)
"Periodontitis is an inflammatory disease that leads to irreversible attachment loss, bone destruction and eventually tooth loss."1.32Polymorphisms in the +252(A/G) lymphotoxin-alpha and the -308(A/G) tumor necrosis factor-alpha genes and susceptibility to chronic periodontitis in a Czech population. ( Buckova, D; Fassmann, A; Holla, LI; Vanek, J; Vasku, A; Znojil, V, 2003)
"Bilateral mechanical hyperalgesia of the paw was induced by administering two injections of acidic saline, 5 d apart, into the gastrocnemius muscle of male Sprague Dawley rats."1.32Phosphorylation of CREB and mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections. ( Hoeger-Bement, MK; Sluka, KA, 2003)
"We present a case in which acute renal failure developed after therapy with tenofovir DF in a patient with HIV and stable chronic kidney disease."1.31Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity. ( Coca, S; Perazella, MA, 2002)
"Adefovir dipivoxil is a prodrug of adefovir designed to enhance its oral bioavailability."1.31Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks. ( Brown, C; Cullen, JM; Cundy, KC; Eisenberg, EJ; Gibbs, C; Li, DH; Toole, J; Wolfe, J, 2001)

Research

Studies (52)

TimeframeStudies, this research(%)All Research%
pre-19901 (1.92)18.7374
1990's5 (9.62)18.2507
2000's20 (38.46)29.6817
2010's21 (40.38)24.3611
2020's5 (9.62)2.80

Authors

AuthorsStudies
Hillmen, P1
Brown, JR1
Eichhorst, BF1
Lamanna, N1
O'Brien, SM1
Qiu, L1
Salmi, T1
Hilger, J1
Wu, K1
Cohen, A1
Huang, J1
Tam, CS1
Gonzalez, RM1
Pidala, J1
Limaye, S1
Limaye, V1
Kaloyannidis, P1
Ayyad, A1
Bahaliwah, Z1
Blowi, B1
Alanazi, W1
Al Shammasi, Z1
Elsoudi, H1
Ibrahim, I1
Al Hashmi, H1
Doki, N1
Toyosaki, M1
Shiratori, S1
Osumi, T1
Okada, M2
Kawakita, T1
Sawa, M1
Ishikawa, T1
Ueda, Y1
Yoshinari, N1
Nakahara, S1
Miklos, D2
Cutler, CS1
Arora, M2
Waller, EK2
Jagasia, M1
Pusic, I2
Flowers, ME1
Logan, AC3
Nakamura, R2
Blazar, BR2
Li, Y1
Chang, S2
Lal, I1
Dubovsky, J1
James, DF1
Styles, L2
Jaglowski, S2
Rahmat, LT1
Jaglowski, SM1
Boudin, L1
Patient, M1
Tsitsi Nding Tsogou, P1
Roméo, E1
Bladé, JS1
de Jauréguiberry, JP1
Wolff, D1
Hilgendorf, I2
Wagner-Drouet, E1
Jedlickova, Z1
Ayuk, F1
Zeiser, R1
Schäfer-Eckart, K1
Gerbitz, A1
Stadler, M1
Klein, S1
Middeke, JM1
Lawitschka, A1
Winkler, J1
Halter, J1
Holler, E1
Kobbe, G1
Stelljes, M1
Ditschkowski, M1
Greinix, H1
Cutler, C1
Jagasia, MH1
Flowers, MED1
Clow, F1
Lal, ID1
Aminzadeh, MA1
Nicholas, SB1
Norris, KC1
Vaziri, ND1
Czech, B1
Dettmer, K1
Valletta, D1
Saugspier, M1
Koch, A1
Stevens, AP1
Thasler, WE1
Müller, M1
Oefner, PJ1
Bosserhoff, AK1
Hellerbrand, C1
Bagcchi, S1
Rozovski, U1
Benjamini, O1
Jain, P1
Thompson, PA1
Wierda, WG1
O'Brien, S1
Burger, JA1
Ferrajoli, A1
Faderl, S1
Shpall, E1
Hosing, C1
Khouri, IF1
Champlin, R1
Keating, MJ1
Estrov, Z1
Hassan, A1
Durlacher, K1
Silver, J3
Naveh-Many, T3
Levi, R1
Lo, YL1
See, SJ1
Tan, CK1
Nechama, M1
Ben-Dov, IZ2
Terai, K1
Nara, H1
Takakura, K1
Mizukami, K1
Sanagi, M1
Fukushima, S1
Fujimori, A1
Itoh, H1
Galitzer, H1
Ikeda, R1
Imai, Y1
Maruyama, W1
Mizoguchi, K1
Ali, BH1
Al-Salam, S1
Al Husseni, I1
Kayed, RR1
Al-Masroori, N1
Al-Harthi, T1
Al Zaabi, M1
Nemmar, A1
Antonioli, L1
Fornai, M1
Colucci, R1
Awwad, O1
Ghisu, N1
Tuccori, M1
Da Settimo, F1
La Motta, C1
Natale, G1
Duranti, E1
Virdis, A1
Blandizzi, C1
Langer, S1
Kokozidou, M1
Heiss, C1
Kranz, J1
Kessler, T1
Paulus, N1
Krüger, T1
Jacobs, MJ1
Lente, C1
Koeppel, TA1
Loebermann, M1
Borchert, K1
Junghanss, C1
Freund, M1
Schmitt, M1
Gracey, D1
Post, J1
MacLeod, C1
McKenzie, P1
Islam, FM1
Wu, J1
Jansson, J1
Wilson, DP1
Ying, H1
Fu, H1
Rose, ML1
McCormack, AM1
Sarathchandra, P1
Okkenhaug, K1
Marelli-Berg, FM1
Leonard, JP1
Coca, S1
Perazella, MA1
Berglundh, T1
Donati, M1
Hahn-Zoric, M1
Hanson, LA1
Padyukov, L1
Sahingur, SE1
Sharma, A1
Genco, RJ1
De Nardin, E1
Louie, M1
Hogan, C1
Hurley, A1
Simon, V1
Chung, C1
Padte, N1
Lamy, P1
Flaherty, J1
Coakley, D1
Di Mascio, M1
Perelson, AS1
Markowitz, M1
Fassmann, A1
Holla, LI1
Buckova, D1
Vasku, A1
Znojil, V1
Vanek, J1
Hoeger-Bement, MK1
Sluka, KA1
Scarel-Caminaga, RM1
Trevilatto, PC1
Souza, AP1
Brito, RB1
Camargo, LE1
Line, SR2
Folwaczny, M1
Glas, J1
Török, HP1
Mende, M1
Folwaczny, C1
Van Rompay, KK1
Singh, RP1
Brignolo, LL1
Lawson, JR1
Schmidt, KA1
Pahar, B1
Canfield, DR1
Tarara, RP1
Sodora, DL1
Bischofberger, N2
Marthas, ML1
Neff, GW1
Nery, J1
Lau, DT1
O'Brien, CB1
Duncan, R1
Shire, NJ1
Ruiz, P1
Nery, C1
Montalbano, M1
Muslu, H1
Safdar, K1
Schiff, ER1
Tzakis, AG1
Madariaga, JR1
Spinazzola, A1
Carrara, F1
Mora, M1
Zeviani, M1
Schildgen, O1
Schewe, CK1
Vogel, M1
Däumer, M1
Kaiser, R1
Weitner, L1
Matz, B1
Rockstroh, JK1
Maier, KP1
Astolfi, CM1
Shinohara, AL1
da Silva, RA1
Santos, MC1
de Souza, AP1
Metzner, KJ1
Binley, JM1
Gettie, A1
Marx, P1
Nixon, DF1
Connor, RI1
de Silva, TI1
Post, FA1
Griffin, MD1
Dockrell, DH1
Tsai, CC1
Follis, KE1
Sabo, A1
Grant, R1
Brand, K1
Dugi, KA1
Brunzell, JD1
Nevin, DN1
Santamarina-Fojo, S1
Zimmerman, SA1
Ware, RE1
Forman, L1
Westwood, B1
Beutler, E1
Gorry, MC1
Gabbaizedeh, D1
Furey, W1
Gates, LK1
Preston, RA1
Aston, CE1
Zhang, Y1
Ulrich, C1
Ehrlich, GD1
Whitcomb, DC1
Cullen, JM1
Li, DH1
Brown, C1
Eisenberg, EJ1
Cundy, KC1
Wolfe, J1
Toole, J1
Gibbs, C1
Korepanov, AM1
Murashov, VS1
Bazhenov, EL1
Chlumský, J1
Hyncík, V1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 3, Randomized Study of Zanubrutinib (BGB-3111) Compared With Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma[NCT03734016]Phase 3652 participants (Actual)Interventional2018-11-01Active, not recruiting
A Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Subjects With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)[NCT03474679]Phase 319 participants (Actual)Interventional2018-05-01Completed
A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease[NCT02195869]Phase 1/Phase 245 participants (Actual)Interventional2014-07-14Completed
Combination Ibrutinib and Rituximab for the Treatment of Chronic Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplant[NCT03689894]Phase 1/Phase 22 participants (Actual)Interventional2019-04-11Terminated (stopped due to Insufficient accrual)
Efficacy and Safety of the Combination of Low-dose Ibrutinib and Itraconazole in Moderate to Severe Chronic Graft Versus Host Disease: a Phase 2 Trial[NCT05348096]Phase 213 participants (Anticipated)Interventional2022-04-01Recruiting
Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients[NCT00551655]684 participants (Actual)Observational2007-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

ORR as Determined by Independent Review Committee (IRC)

"ORR is the percentage of participants with PR or higher, (CR/CRi) + PR + nodular PR per IRC assessment using the modified 2008 IWCLL guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for NHL for participants with SLL" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months

InterventionPercentage of participants (Number)
Zanubrutinib86.2
Ibrutinib75.7

Overall Response Rate (ORR) as Determined by Investigator Assessment

"ORR is percentage of participants with partial response (PR) or higher, (defined as Complete response/ Complete response with incomplete bone marrow recovery (CR/CRi) + PR + nodular PR) per investigator assessment using the modified 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) guidelines with modification for treatment-related lymphocytosis for participants with CLL and per Lugano Classification for non-Hodgkin lymphoma (NHL)) for participants with Small lymphocytic lymphoma (SLL)" (NCT03734016)
Timeframe: Up to approximately 3 years and 9 months

InterventionPercentage of participants (Number)
Zanubrutinib83.5
Ibrutinib74.2

Duration of Response (DOR)

DOR is defined as the duration from the date of initial response (CR or PR) to the date of progressive cGVHD or death, whichever occurred first. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs. (NCT03474679)
Timeframe: Up to 3 year 6 months

InterventionMonths (Median)
Ibrutinib 420 mgNA

Number of Participants With Treatment-emergent Adverse Events (TEAEs)

An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. TEAEs are adverse events with onset during the treatment phase or that were a consequence of a preexisting condition that has worsened since baseline, and occurred during treatment or within 30 days following the last dose of study treatment, or any adverse event that was considered study treatment-related regardless of the start date of the event. (NCT03474679)
Timeframe: Up to 3 year 6 months

InterventionParticipants (Count of Participants)
Ibrutinib 420 mg19

Overall Response Rate (ORR)

ORR is defined as the percentage of participants who achieve complete response (CR) or partial response (PR) in the absence of new therapy for chronic graft versus host disease (cGVHD) and absence of progression of underlying disease or death based on the National Institutes of Health (NIH) Consensus Development Project Criteria (2014). CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site; and chronic graft versus host disease (cGVHD) progression is defined as clinically meaningful worsening in 1 or more organs regardless of improvement in other organs. (NCT03474679)
Timeframe: Up to 3 year 6 months

InterventionPercentage of participants (Number)
Ibrutinib 420 mg84.2

Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Scale Score

Percentage of participants with overall improvement in Lee cGVHD symptom scale score was reported. Lee cGVHD symptom scale is a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing a better outcome. A score was calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 with a higher score indicating worse symptoms. An overall score was calculated as the average of these 7 subscales if at least 4 subscales had valid scores. A change of greater than or equal to (>=) 7 points on the Lee cGVHD symptom scale overall score was considered significant and relates to improvement in quality of life (QoL). (NCT03474679)
Timeframe: Up to 3 year 6 months

InterventionPercentage of participants (Number)
Ibrutinib 420 mg52.6

Sustained Response Rate

Sustained response rate was defined as percentage of participants with NIH defined CR or PR that was sustained for at least 20 weeks. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site. (NCT03474679)
Timeframe: Up to 3 year 6 months

InterventionPercentage of participants (Number)
Ibrutinib 420 mg68.8

Apparent Clearance (CL/F) of Ibrutinib

CL/F is defined as apparent clearance of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionMilliliters per hour (mL/h) (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg194211162457

Apparent Clearance (CL/F) of PCI-45227

CL/F is defined as apparent clearance of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionmL/h (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg251681111922

Apparent Volume of Distribution (Vd/F) of Ibrutinib

Vd/F is defined as apparent volume of distribution of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionMilliliters (mL) (Mean)
Week 1: Day 1
Ibrutinib 420 mg1350160

Apparent Volume of Distribution (Vd/F) of PCI-45227

Vd/F is defined as apparent volume of distribution of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionmL (Mean)
Week 1: Day 1
Ibrutinib 420 mg2148283

Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC [0-24]) of Ibrutinib

AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of ibrutinib. (NCT03474679)
Timeframe: 0 to 24 hours (Day 1 of Weeks 1 and 2)

Interventionhour*ng/mL (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg2929.34035.6

Area Under the Plasma Concentration-Time Curve From Time Zero to 24 Hours (AUC [0-24]) of PCI-45227

AUC(0-24) is defined as area under the plasma concentration-time curve from time zero to 24 hours of PCI-45227. (NCT03474679)
Timeframe: 0 to 24 hours (Day 1 of Weeks 1 and 2)

Interventionhour*ng/mL (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg1803.02547.6

Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of Ibrutinib

AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

Interventionhour*ng/mL (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg2643.82659.2

Area Under the Plasma Concentration-time Curve From Time Zero to Infinite Time (AUC[0-infinity]) of PCI-45227

AUC(0-infinity) is defined as area under the plasma concentration-time curve from time zero to infinite time of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

Interventionhour*ng/mL (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg1766.13752.6

Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of Ibrutinib

AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

Interventionhours*nanograms per milliliter (h*ng/mL) (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg3683.74024.8

Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Measurable Concentration (AUC [0-last]) of PCI-45227

AUC(0-last) is defined as area under the plasma concentration-time curve from time zero to time of last measurable concentration of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

Interventionh*ng/mL (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg1976.92547.6

cGVHD Response Rate at Each Timepoints

cGVHD response rate was defined as percentage of participants with NIH defined CR or PR at each timepoint. CR is defined as resolution of all manifestations in each organ or site; PR is defined as improvement in at least 1 organ or site without progression in any other organ or site. (NCT03474679)
Timeframe: Weeks 5, 13, 25, 37, 49, 61, 73, 85, 97, 109, 121, 133, 145, 157

InterventionPercentage of participants (Number)
Week 5Week 13Week 25Week 37Week 49Week 61Week 73Week 85Week 97Week 109Week 121Week 133Week 145Week 157
Ibrutinib 420 mg26.342.152.647.447.442.136.831.631.631.636.831.626.310.5

Change in the Amount of Corticosteroid Required Over Time

Change in the amount of corticosteroid required over time was reported. (NCT03474679)
Timeframe: Baseline, Weeks 24, 48, 96, and 144

InterventionMilligrams per kilograms per day (Median)
BaselineWeek 24Week 48Week 96Week 144
Ibrutinib 420 mg0.2700.2500.1500.1400.140

Elimination Half-Life (t1/2) of Ibrutinib

T1/2 is defined as elimination half-life of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionHours (Median)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg4.94.4

Elimination Half-Life (t1/2) of PCI-45227

T1/2 is defined as elimination half-life of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionHours (Median)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg5.95.4

Maximum Observed Plasma Concentration (Cmax) of Ibrutinib

Cmax is defined as maximum observed plasma concentration of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionNanograms per milliliter (ng/mL) (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg490.45478.01

Maximum Observed Plasma Concentration (Cmax) of PCI-45227

Cmax is defined as maximum observed plasma concentration of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

Interventionng/mL (Mean)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg185.37203.16

Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ibrutinib

Tmax is defined as time to reach the maximum observed plasma concentration of ibrutinib. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionHours (Median)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg3.874.02

Time to Reach Maximum Observed Plasma Concentration (Tmax) of PCI-45227

Tmax is defined as time to reach the maximum observed plasma concentration of PCI-45227. (NCT03474679)
Timeframe: Day 1 of Weeks 1 and 2

InterventionHours (Median)
Week 1: Day 1Week 2: Day 1
Ibrutinib 420 mg4.004.02

Percentage of Participants With Overall Improvement in Lee cGVHD Symptom Summary Score

"Subject reported improvement in symptom burden. The symptom burden will be measured according to the Lee cGVHD Symptom Scale. A change in >7 points on the Lee cGVHD Symptom Scale will be considered significant and relates to improvement in quality of life.~A score is calculated for each subscale by taking the mean of all items completed if more than 50% were answered and normalizing to a 0 to 100 scale. A total summary score is calculated as the average of these 7 subscales if at least 4 subscales have valid scores.~There are 7 subscales (Skin, Energy, Lung, Eye, Nutrition, Mouth and Psychological) with ratings as follow: 0- Not at all, 1- Slightly, 2 Moderately, 3 Quite a bit, 4-Extremely; with a lower values representing a better outcome." (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

Interventionpercentage of participants (Number)
Phase 1b/Phase 242.9

Phase 1b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD.

Number of participants with dose-limiting toxicities as a measure of safety profile to determine recommended dose of ibrutinib (NCT02195869)
Timeframe: 28 treatment days after last subject enrolled in Phase 1 dose level(s).

InterventionParticipants (Count of Participants)
Phase 1b: Dose Level 10

Phase 2: Overall Response Rate as the Percentage of Participants With Response

Overall Response Rate is defined as the proportion of subjects who achieved complete response (CR) or partial response (PR). Response criteria are based on NIH cGVHD Response assessment (Pavletic 2006; Measurement of Therapeutic Response, ASBMT Web site). (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

Interventionpercentage of participants (Number)
Phase1b/Phase 269

Phase 2b: To Evaluate the Safety and Tolerability of Ibrutinib in Steroid Dependent/Refractory cGVHD

Number of Participants With Adverse Events as a Measure of Safety and Tolerability of Ibrutinib (NCT02195869)
Timeframe: From first dose with study drug until 30 days after the last dose of study drug, up to 36.7 months

InterventionParticipants (Count of Participants)
Phase 1b/Phase 242

Sustained Response Rate as the Percentage of Participants With Sustained Response

For subjects who achieved an NIH-defined CR or PR, the proportion of subjects who achieved CR or PR that was sustained for at least 20 weeks (140 days). Intermittent SD was also acceptable. (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

Interventionpercentage of participants (Number)
Phase1b/Phase 269

To Evaluate the Clinical Efficacy of Ibrutinib in Steroid Dependent/Refractory cGVHD by Measuring: Duration of Response (DOR)

For subjects who achieved an NIH-defined CR or PR, the interval between the date of initial documentation of a response and the date of first documented evidence of PD, death, or date of censoring if applicable. (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

InterventionMedian (Median)
Phase1b/Phase 2NA

Corticosteroid Requirement Changes Over Time

Average daily corticosteroid dose assessed each week. (NCT02195869)
Timeframe: Analysis was conducted with the data extraction date of 15 Sep 2017, with a median follow-up time of 25.56 months.

InterventionDaily Dose of Steroid by Weight (mg/kg/d (Median)
Week 1Week 2Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10Week 11Week 12Week 13Week 14Week 15Week 16Week 17Week 18Week 19Week 20Week 21Week 22Week 23Week 24Week 25Week 26Week 27Week 28Week 29Week 30Week 31Week 32Week 33Week 34Week 35Week 36Week 37Week 38Week 39Week 40Week 41Week 42Week 43Week 44Week 45Week 46Week 47Week 48Week 49Week 50Week 51Week 52Week 53Week 54Week 55Week 56Week 57Week 58Week 59Week 60Week 61Week 62Week 63Week 64Week 65Week 66Week 67Week 68Week 69Week 70Week 71Week 72Week 73Week 74Week 75Week 76Week 77Week 78Week 79Week 80Week 81Week 82Week 83Week 84Week 85Week 86Week 87Week 88Week 89Week 90Week 91Week 92Week 93Week 94Week 95Week 96Week 97Week 98Week 99Week 100Week 101Week 102Week 103Week 104Week 105Week 106Week 107Week 108Week 109Week 110Week 111Week 112Week 113Week 114Week 115Week 116Week 117Week 118Week 119Week 120Week 121Week 122Week 123Week 124Week 125Week 126Week 127Week 128Week 129Week 130Week 131Week 132Week 133Week 134Week 135Week 136Week 137Week 138Week 139Week 140Week 141Week 142Week 143Week 144Week 145Week 146Week 147Week 148Week 149Week 150Week 151Week 152Week 153Week 154Week 155Week 156Week 157Week 158Week 159Week 160
Phase 1b/Phase 20.310.320.320.310.310.300.300.300.270.250.250.250.240.230.230.230.210.200.200.210.220.220.220.210.190.180.180.180.160.160.160.180.170.170.180.180.160.150.150.150.150.150.130.130.130.130.130.130.120.100.100.100.100.100.100.100.100.100.100.080.080.080.080.080.080.080.080.080.080.080.070.080.080.070.070.070.070.070.070.070.070.070.070.070.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.080.090.090.090.090.080.080.080.080.080.080.080.080.080.080.120.120.080.080.080.080.080.120.080.080.080.080.080.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.000.060.060.06

Assess the Response Rate of cGVHD to Treatment With Ibrutinib Plus Rituximab

Response rate of clinically significant GVHD will be assessed using NIH criteria (from 2014 NIH Consensus Development Project). (NCT03689894)
Timeframe: 6 weeks, 3 months, and 6 months after initiation of treatment

InterventionParticipants (Count of Participants)
Ibrutinib Plus Rituximab0

Reviews

7 reviews available for adenine and Chronic Illness

ArticleYear
Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
    Pharmacotherapy, 2020, Volume: 40, Issue:8

    Topics: Adenine; Adrenal Cortex Hormones; Chronic Disease; Cyclophosphamide; Graft vs Host Disease; Hematopo

2020
Clinical Characteristics of Myositis Associated with Graft-Versus-Host Disease.
    Current rheumatology reports, 2021, 04-24, Volume: 23, Issue:5

    Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; My

2021
Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy.
    Drugs of today (Barcelona, Spain : 1998), 2018, Volume: 54, Issue:5

    Topics: Adenine; Animals; Chronic Disease; Drug Interactions; Graft vs Host Disease; Humans; Piperidines; Py

2018
How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD.
    Blood advances, 2018, 08-14, Volume: 2, Issue:15

    Topics: Adenine; Animals; B-Lymphocytes; Chronic Disease; Drug Approval; Drug Resistance; Graft vs Host Dise

2018
Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis.
    BMC public health, 2012, Mar-23, Volume: 12

    Topics: Acquired Immunodeficiency Syndrome; Adenine; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Chronic

2012
[Drug therapy in chronic liver disease].
    Praxis, 2005, Nov-30, Volume: 94, Issue:48

    Topics: Adenine; Administration, Oral; Anti-HIV Agents; Antiviral Agents; Azathioprine; Cholangitis, Scleros

2005
HIV-1 infection and the kidney: an evolving challenge in HIV medicine.
    Mayo Clinic proceedings, 2007, Volume: 82, Issue:9

    Topics: Acute Disease; Acute Kidney Injury; Adenine; AIDS-Associated Nephropathy; Angiotensin-Converting Enz

2007

Trials

5 trials available for adenine and Chronic Illness

ArticleYear
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Future oncology (London, England), 2020, Volume: 16, Issue:10

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Chronic Disease; Clinical Trials, Phase III as Topic;

2020
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:10

    Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles;

2021
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:10

    Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles;

2021
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:10

    Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles;

2021
An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
    Transplantation and cellular therapy, 2021, Volume: 27, Issue:10

    Topics: Adenine; Adolescent; Chronic Disease; Graft vs Host Disease; Humans; Japan; Piperidines; Pyrazoles;

2021
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Blood, 2017, 11-23, Volume: 130, Issue:21

    Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro

2017
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Blood, 2017, 11-23, Volume: 130, Issue:21

    Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro

2017
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Blood, 2017, 11-23, Volume: 130, Issue:21

    Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro

2017
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.
    Blood, 2017, 11-23, Volume: 130, Issue:21

    Topics: Adenine; Adrenal Cortex Hormones; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Biomarkers; Chro

2017
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:10

    Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim

2019
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:10

    Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim

2019
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:10

    Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim

2019
Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:10

    Topics: Adenine; Chronic Disease; Female; Graft vs Host Disease; Humans; Male; Piperidines; Pyrazoles; Pyrim

2019
Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals.
    AIDS (London, England), 2003, May-23, Volume: 17, Issue:8

    Topics: Adenine; Adult; Anti-HIV Agents; Chronic Disease; Female; HIV Infections; HIV-1; Humans; Male; Middl

2003

Other Studies

40 other studies available for adenine and Chronic Illness

ArticleYear
Ibrutinib for steroid refractory chronic graft-versus-host disease: therapeutic efficiency can be limited by increased risk of fungal infection.
    Bone marrow transplantation, 2021, Volume: 56, Issue:8

    Topics: Adenine; Chronic Disease; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; My

2021
Successful treatment with ribavirine for chronic hepatitis E in chronic lymphocytic leukemia treated with Ibrutinib.
    Bulletin du cancer, 2019, Volume: 106, Issue:1

    Topics: Adenine; Aged; Alemtuzumab; Antineoplastic Agents, Immunological; Antiviral Agents; Chronic Disease;

2019
Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:7

    Topics: Adenine; Adult; Austria; Bronchiolitis Obliterans; Chronic Disease; Female; Germany; Graft vs Host D

2019
Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2013, Volume: 28, Issue:8

    Topics: Adenine; Animals; Arachidonate 12-Lipoxygenase; Blotting, Western; Catalase; Chronic Disease; Cycloo

2013
Expression and function of methylthioadenosine phosphorylase in chronic liver disease.
    PloS one, 2013, Volume: 8, Issue:12

    Topics: Adenine; Animals; Apoptosis; Chronic Disease; Gene Expression Regulation; Hepatic Stellate Cells; He

2013
Ibrutinib monotherapy in chronic lymphoid leukaemia.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humani

2014
Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter's Transformation After Transplantation Failure.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, May-10, Volume: 33, Issue:14

    Topics: Adenine; Adult; Aged; Antineoplastic Agents; Chronic Disease; Disease Progression; Factor Analysis,

2015
The fibroblast growth factor receptor mediates the increased FGF23 expression in acute and chronic uremia.
    American journal of physiology. Renal physiology, 2016, Feb-01, Volume: 310, Issue:3

    Topics: Acute Kidney Injury; Adenine; Animals; Chronic Disease; Disease Models, Animal; Fibroblast Growth Fa

2016
Continuous single motor unit electromyographic activity in adefovir associated myopathy.
    Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2008, Volume: 15, Issue:9

    Topics: Adenine; Antiviral Agents; Chronic Disease; Creatine Kinase; Electromyography; Hepatitis B; Humans;

2008
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
    American journal of physiology. Renal physiology, 2009, Volume: 296, Issue:4

    Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Mode

2009
Vascular calcification and secondary hyperparathyroidism of severe chronic kidney disease and its relation to serum phosphate and calcium levels.
    British journal of pharmacology, 2009, Volume: 156, Issue:8

    Topics: Adenine; Animals; Aortic Diseases; Biomarkers; Blood Urea Nitrogen; Calcinosis; Calcium; Calcium Car

2009
Parathyroid cell resistance to fibroblast growth factor 23 in secondary hyperparathyroidism of chronic kidney disease.
    Kidney international, 2010, Volume: 77, Issue:3

    Topics: Adenine; Animals; Chronic Disease; Down-Regulation; Fibroblast Growth Factor-23; Fibroblast Growth F

2010
Systemic disorders of calcium dynamics in rats with adenine-induced renal failure: implication for chronic kidney disease-related complications.
    Nephrology (Carlton, Vic.), 2010, Volume: 15, Issue:1

    Topics: Adenine; Animals; Calcium Metabolism Disorders; Chronic Disease; Male; Rats; Rats, Inbred F344; Rena

2010
Effects of Gum Arabic in rats with adenine-induced chronic renal failure.
    Experimental biology and medicine (Maywood, N.J.), 2010, Volume: 235, Issue:3

    Topics: Adenine; Animals; Anti-Inflammatory Agents; Antioxidants; Chronic Disease; Disease Models, Animal; D

2010
The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors.
    The Journal of pharmacology and experimental therapeutics, 2010, Volume: 335, Issue:2

    Topics: Adenine; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blotting, Western; Body Weigh

2010
Chronic kidney disease aggravates arteriovenous fistula damage in rats.
    Kidney international, 2010, Volume: 78, Issue:12

    Topics: Adenine; Animals; Arteriovenous Shunt, Surgical; Blood Pressure; Calcinosis; Chronic Disease; Constr

2010
Tenofovir for treatment of hepatitis B virus reactivation in patients with chronic GVHD.
    Bone marrow transplantation, 2011, Volume: 46, Issue:9

    Topics: Adenine; Adult; Chronic Disease; Female; Graft vs Host Disease; Hepatitis B virus; Hepatitis B, Chro

2011
Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
    Nephrology (Carlton, Vic.), 2011, Volume: 16, Issue:4

    Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Biopsy; Chronic Disease

2011
Genetic or pharmaceutical blockade of phosphoinositide 3-kinase p110δ prevents chronic rejection of heart allografts.
    PloS one, 2012, Volume: 7, Issue:3

    Topics: Adenine; Animals; Cells, Cultured; Chronic Disease; Class Ia Phosphatidylinositol 3-Kinase; Female;

2012
Is rituximab maintenance still standard of care in indolent non-hodgkin lymphoma?
    Clinical advances in hematology & oncology : H&O, 2012, Volume: 10, Issue:8

    Topics: Adenine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-D

2012
Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.
    The American journal of the medical sciences, 2002, Volume: 324, Issue:6

    Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Chronic Disease; HIV Infections; Humans; Kidne

2002
Association of the -1087 IL 10 gene polymorphism with severe chronic periodontitis in Swedish Caucasians.
    Journal of clinical periodontology, 2003, Volume: 30, Issue:3

    Topics: Adenine; Adult; Aged; Alleles; Alveolar Bone Loss; Chi-Square Distribution; Chronic Disease; Confide

2003
Association of increased levels of fibrinogen and the -455G/A fibrinogen gene polymorphism with chronic periodontitis.
    Journal of periodontology, 2003, Volume: 74, Issue:3

    Topics: 5' Flanking Region; Adenine; Age Factors; Aged; Alleles; Analysis of Variance; Case-Control Studies;

2003
Polymorphisms in the +252(A/G) lymphotoxin-alpha and the -308(A/G) tumor necrosis factor-alpha genes and susceptibility to chronic periodontitis in a Czech population.
    Journal of periodontal research, 2003, Volume: 38, Issue:4

    Topics: Adenine; Adult; Case-Control Studies; Chronic Disease; Czech Republic; Female; Gene Frequency; Genet

2003
Phosphorylation of CREB and mechanical hyperalgesia is reversed by blockade of the cAMP pathway in a time-dependent manner after repeated intramuscular acid injections.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2003, Jul-02, Volume: 23, Issue:13

    Topics: Acids; Adenine; Adenylyl Cyclase Inhibitors; Animals; Behavior, Animal; Chronic Disease; Cyclic AMP;

2003
Interleukin 10 gene promoter polymorphisms are associated with chronic periodontitis.
    Journal of clinical periodontology, 2004, Volume: 31, Issue:6

    Topics: Adenine; Adult; Chronic Disease; Cytosine; Female; Gene Frequency; Genetic Predisposition to Disease

2004
Lack of association between the TNF alpha G -308 A promoter polymorphism and periodontal disease.
    Journal of clinical periodontology, 2004, Volume: 31, Issue:6

    Topics: Adenine; Adult; Aged; Alleles; Chronic Disease; Female; Gene Frequency; Genetic Predisposition to Di

2004
The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters.
    Journal of acquired immune deficiency syndromes (1999), 2004, Aug-01, Volume: 36, Issue:4

    Topics: Adenine; Animals; Animals, Newborn; Anti-HIV Agents; Antibodies, Viral; CD4-Positive T-Lymphocytes;

2004
Tenofovir therapy for lamivudine resistance following liver transplantation.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:12

    Topics: Adenine; Adult; Antiviral Agents; Chronic Disease; Drug Resistance, Viral; Hepatitis B; Hepatitis B,

2004
Mitochondrial myopathy and ophthalmoplegia in a sporadic patient with the 5698G-->A mitochondrial DNA mutation.
    Neuromuscular disorders : NMD, 2004, Volume: 14, Issue:12

    Topics: Adenine; Aged; Base Sequence; Chronic Disease; DNA, Mitochondrial; Electron Transport Complex IV; Gu

2004
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
    AIDS (London, England), 2004, Nov-19, Volume: 18, Issue:17

    Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directe

2004
Genetic polymorphisms in the MMP-1 and MMP-3 gene may contribute to chronic periodontitis in a Brazilian population.
    Journal of clinical periodontology, 2006, Volume: 33, Issue:10

    Topics: Adenine; Adult; Alleles; Brazil; Chronic Disease; Female; Gene Frequency; Genetic Predisposition to

2006
Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
    Retrovirology, 2006, Dec-21, Volume: 3

    Topics: Adenine; Animals; Anti-HIV Agents; Antibodies, Viral; CD8-Positive T-Lymphocytes; Chronic Disease; D

2006
Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques.
    The Journal of infectious diseases, 1995, Volume: 171, Issue:5

    Topics: Adenine; Animals; Antiviral Agents; Chronic Disease; DNA, Viral; Leukocytes, Mononuclear; Lymphocyte

1995
A novel A-->G mutation in intron I of the hepatic lipase gene leads to alternative splicing resulting in enzyme deficiency.
    Journal of lipid research, 1996, Volume: 37, Issue:6

    Topics: Adenine; Alternative Splicing; Amino Acid Sequence; Base Sequence; Child; Chronic Disease; DNA Prime

1996
Glucose-6-phosphate dehydrogenase Durham: a de novo mutation associated with chronic hemolytic anemia.
    The Journal of pediatrics, 1997, Volume: 131, Issue:2

    Topics: Adenine; Amino Acid Sequence; Anemia, Hemolytic, Congenital Nonspherocytic; Arginine; Base Sequence;

1997
Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis.
    Gastroenterology, 1997, Volume: 113, Issue:4

    Topics: Acute Disease; Adenine; Asparagine; Chromosome Mapping; Chromosomes, Human, Pair 7; Chronic Disease;

1997
Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks.
    Antimicrobial agents and chemotherapy, 2001, Volume: 45, Issue:10

    Topics: Adenine; Administration, Oral; Animals; Chemistry, Clinical; Chronic Disease; Disease Models, Animal

2001
[The dynamics of the indices of protein metabolic homeostasis and the status of duodenal mucosal regeneration during the etaden treatment of duodenal peptic ulcer].
    Terapevticheskii arkhiv, 1992, Volume: 64, Issue:2

    Topics: Adenine; Adolescent; Adult; Anti-Ulcer Agents; Chronic Disease; Drug Evaluation; Duodenal Ulcer; Duo

1992
[Problem of active therapeutic procedure in chronic liver disease].
    Casopis lekaru ceskych, 1972, Aug-04, Volume: 111, Issue:32

    Topics: Adenine; Adult; Aged; Chronic Disease; Diet Therapy; Female; Humans; Inositol; Liver Diseases; Male;

1972